Skip to Content

Mylanta AR (famotidine) Disease Interactions

There are 2 disease interactions with Mylanta AR (famotidine):


H2 antagonists (Includes Mylanta AR) ↔ GI bleeding

Severe Potential Hazard, Moderate plausibility. Applies to: Gastrointestinal Hemorrhage

Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools. These might be serious conditions and the diagnosis needs to be ruled out.


Famotidine (Includes Mylanta AR) ↔ renal dysfunction

Moderate Potential Hazard, High plausibility. Applies to: Renal Dysfunction

Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous). The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients. Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients. Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient's clinical response.


  1. Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987): 782-7
  2. Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987): 458-63
  3. Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985): 327-31
  4. Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994): 393-408
  5. "Product Information. Pepcid (famotidine)." Merck & Co, Inc, West Point, PA.
  6. Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988): 315-21
  7. Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988): 656-63
View all 7 references

Mylanta AR (famotidine) drug interactions

There are 396 drug interactions with Mylanta AR (famotidine)

Mylanta AR (famotidine) alcohol/food interactions

There is 1 alcohol/food interaction with Mylanta AR (famotidine)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.